NP-313 (0-80 μM) inhibits platelet aggregation in a dose-dependent manner. The maximum inhibition of platelet aggregation induced by thrombin and A23187 was approximately 80% and 60%, respectively[1].
NP-313 (0-8 μM) concentration-dependently inhibited P-selectin expression and thromboxane B 2 (TXB2) production in human platelets induced by collagen or thrombin. Also, NP-313 inhibited COX-1 and TXA 2 synthase with the IC 50 values of 1.5 and 3.9 µM, respectively[1].
NP-313 (i.v., 4-16 µg/g) significantly prolongs occlusion time (TTO), prolongs bleeding time and inhibits platelet aggregation induced by collagen (10 µg/mL) in male ICR mice[1].
References:
[1]. Heng-Lan Kuo, et al. NP-313, 2-acetylamino-3-chloro-1,4-naphthoquinone, a novel antithrombotic agent with dual inhibition of thromboxane A(2) synthesis and calcium entry. Br J Pharmacol. 2011 Apr;162(8):1871-83.